Marinus Pharma (MRNS) Says Primary Endpoint Not Met in Ganaxolone Phase 2 Exploratory Study
Tweet Send to a Friend
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) announced top-line data from a Phase 2 exploratory, investigator-sponsored study to evaluate the safety, tolerability ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
